TABLE 3.

Pharmacokinetic data for subjects experiencing grade 2 adverse events

Subject	Dose (mg)	Dose (mg/kg)a	Dose range (mg/kg) for cohort	Grade 2 adverse event	Cmax (ng/ml)	AUC (ng · h/ml)	Mean AUC (ng · h/ml) for cohort	AUC range (ng · h/ml) for cohort
206	400	4.7∗	4.3–6.1	Abdominal painb	1,186	4,305	9,570	1,761–14,858
212	400	6.0†	4.3–6.1	Dizziness	1,117	11,173	9,570	1,761–14,858
212	400	6.0†	4.3–6.1	Nausea	1,117	11,173	9,570	1,761–14,858
212	400	6.0†	4.3–6.1	Vomiting (gagging, no emesis)	1,117	11,173	9,570	1,761–14,858
306	600	9.0†	7.3–10.8	Dizziness	2,308	10,445	12,973	1,840–15,328
311	600	7.5∗	7.3–10.8	Arthralgia and arthritisb	325	1,840	12,973	1,840–15,328
314	600	8.5∗	7.3–10.8	Hypertensionb	1,370	8,247	12,973	1,840–15,328
315	600	10.8†	7.3–10.8	Pharyngitisb	3,443	14,746	12,973	1,840–15,328

^a∗, subject was fed prior to dosing; †, subject was fasted prior to dosing. 

^bConsidered by investigator to be unrelated to dosing.